Ascelia Pharma: Market is pricing the downside, but the CRL letter and management commentary still support better scenarios
15 juli, 08:03
Following the FDA's Complete Response Letter for Orviglance and the subsequent publication of the redacted letter, we set out what the current share price implies, the scenarios we see into the Type A meeting, and our reading of the clinical issue at the centre of the case.
Ämnen i artikeln
Ascelia Pharma: Market is pricing the downside, but the CRL letter and management commentary still support better scenarios
15 juli, 08:03
Following the FDA's Complete Response Letter for Orviglance and the subsequent publication of the redacted letter, we set out what the current share price implies, the scenarios we see into the Type A meeting, and our reading of the clinical issue at the centre of the case.
Ämnen i artikeln
Inflationen
Experterna om börsen
Privatekonomi
Inflationen
Experterna om börsen
Privatekonomi
Marknadsöversikt
1 DAG %
Senast
1 mån
